SAN DIEGO, June 11, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ:NBIX) today announced that on
June 11, 2014, two scientific posters
associated with its study of NBI-98854 in Phase IIb clinical trials
of tardive dyskinesia patients, will be presented at the 2014
Annual Congress of Parkinson's Disease and Movement Disorders in
Stockholm Sweden. This annual
meeting brings together over 5,000 clinicians and scientists from
around the world to address current topics related to movement
disorders.
The posters (abstracts #826 and #829) titled
"Kinect 1 Extension: 12-week treatment of Tardive
Dyskinesia with NBI-98854" and "Kinect 2: NBI-98854 Treatment
of Moderate to Severe Tardive Dyskinesia" are available
throughout the day, with the guided poster session occurring from
12:00pm to 1:30pm CET on June 11, 2014. Both of these posters
describe the methodology of each clinical trial, safety and
efficacy results, and statistical findings along with key clinical
observations.
"Having both of these posters accepted for presentation at this
important meeting allows us to share the breadth and depth of our
tardive dyskinesia clinical efforts with the worldwide experts in
movement disorders," said Chris
O'Brien, M.D., Chief Medical Officer at Neurocrine. "These
presentations describe the conduct and outcomes of two rigorous,
well-controlled clinical trials in tardive dyskinesia, representing
a significant advance for this therapeutic area. Our team is
looking forward to presenting and discussing this data at the
Annual Congress of Parkinson's Disease and Movement
Disorders."
About NBI-98854
VMAT2 is a protein concentrated in the human brain that is
primarily responsible for re-packaging and transporting monoamines
(dopamine, norepinephrine, serotonin, and histamine) in
pre-synaptic neurons. NBI-98854, developed in the Neurocrine
laboratories, is a novel, highly-selective VMAT2 inhibitor that
modulates dopamine release during nerve communication, while at the
same time having minimal impact on the other monoamines, thereby
reducing the likelihood of "off target" side effects.
NBI-98854 is designed to provide low, sustained, plasma and brain
concentrations of active drug to minimize side effects associated
with excessive monoamine depletion. The Company is currently
preparing for an end of phase II meeting with the FDA related to
utilizing NBI-98854 in patients with tardive dyskinesia.
NBI-98854 may also be useful in other disorders such as
Huntington's chorea, schizophrenia, Tourette's syndrome, and
tardive dystonia.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, as well as
risks and uncertainties associated with the Company's VMAT2 program
and Company overall. Specifically, the risks and uncertainties the
Company faces with respect to the Company's VMAT2 program include,
but are not limited to; risk that NBI-98854 will not proceed to
later stage clinical trials and risk that the Company's clinical
trials will fail to demonstrate that NBI-98854 is safe and
effective as well as the other risks described in the
Company's report on Form 10-K for the year ended December 31, 2013 and Form 10-Q for the quarter
ended March 31, 2014. Neurocrine
undertakes no obligation to update the statements contained in this
press release after the date hereof.
SOURCE Neurocrine Biosciences, Inc.